Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma.

J.D. Morrow,J.A. Awad,K. Takahashi,L.J. Roberts

doi:10.1016/s0021-9258(18)53593-6

Abstract

Free radicals are thought to play an important role in many types of tissue injury. Recently, we reported that a series of prostaglandin F2-like compounds (F2-isoprostanes) capable of exerting potent biological activity are produced in vivo by free radical-induced lipid peroxidation. Their formation is independent of the cyclooxygenase enzyme and has been shown to increase profoundly in animal models of free radical injury and lipid peroxidation. We now report the identification of F-ring isoprostane metabolites in human urine and plasma utilizing a gas chromatographic/mass spectrometric assay for the major urinary metabolite of prostaglandin D2 (9 alpha,11 beta-dihydroxy-15-oxo-2,3, 18,19-tetranorprost-5-ene-1,20-dioic acid). Evidence confirming these metabolites as tetranor, dicarboxylic acid compounds containing one double bond, cis-cyclopentane ring hydroxyls, and one keto group similar in structure to the major urinary metabolite of prostaglandin D2 was obtained by analysis of human urine by electron ionization mass spectrometry. Levels of these metabolites in normal human urine were determined and found to be unaffected by cyclooxygenase inhibitors. Evidence that these metabolites arise from F2-isoprostanes was obtained by demonstrating that (a) marked increases in plasma levels and urinary excretion of these metabolites, which were unaffected by coadministration of indomethacin, occurred in rats administered CCl4 to induce F2-isoprostane formation and (b) marked increases in levels of these metabolites in plasma and urine resulted from the intravenous infusion of F2-isoprostanes into a rat. Quantification of these isoprostane metabolites in urine and plasma may provide a reliable index of endogenous isoprostane production which could prove to be an important advance in our ability to assess oxidant stress in vivo in humans.

Highlights

F,isoprostanes was obtained by demonstrating that (a)markedincreasesinplasmalevelsandurinary excretion of these metabolites, which were unaffected by coadministration of indomethacin, occurred in rats administered CC1, to induce Fz-isoprostane formation and ( b )marked increases in levelosf these metabolites in plasma and urine resulted from the intravenous infusion of Fz-isoprostanes intoa rat
The columns were washed with 10 ml of pH 3 Hz0 followed by 10 ml of heptane and themetabolites eluted with 10 ml of ethyl acetate/heptane (5050)
The residue was resuspended in 10 mlof methanol, methylated by adding excess ethereal diazomethane for 5

Summary

Introduction

F,-isoprostanes was obtained by demonstrating that (a)markedincreasesinplasmalevelsandurinary excretion of these metabolites, which were unaffected by coadministration of indomethacin, occurred in rats administered CC1, to induce Fz-isoprostane formation and ( b )marked increases in levelosf these metabolites in plasma and urine resulted from the intravenous infusion of Fz-isoprostanes intoa rat. Analysis of urine from an individual boronate derivative resulting in a shift of the M 181ion to treated with indomethacin to suppress PGD-M production m/z 438 consistent with the presence of cis-oriented hydroxyl illustrates this fact (Fig. 3B).

Results

Conclusion